505 related articles for article (PubMed ID: 27464719)
1. Targeted Vascular Drug Delivery in Cerebral Cancer.
Humle N; Johnsen KB; Arendt GA; Nielsen RP; Moos T; Thomsen LB
Curr Pharm Des; 2016; 22(35):5487-5504. PubMed ID: 27464719
[TBL] [Abstract][Full Text] [Related]
2. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
3. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.
Sarkaria JN; Hu LS; Parney IF; Pafundi DH; Brinkmann DH; Laack NN; Giannini C; Burns TC; Kizilbash SH; Laramy JK; Swanson KR; Kaufmann TJ; Brown PD; Agar NYR; Galanis E; Buckner JC; Elmquist WF
Neuro Oncol; 2018 Jan; 20(2):184-191. PubMed ID: 29016900
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
Wang D; Wang C; Wang L; Chen Y
Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
[TBL] [Abstract][Full Text] [Related]
5. Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: therapeutic promise for combating glioblastoma.
Saha S; Yakati V; Shankar G; Jaggarapu MMCS; Moku G; Madhusudana K; Banerjee R; Ramkrishna S; Srinivas R; Chaudhuri A
J Mater Chem B; 2020 May; 8(19):4318-4330. PubMed ID: 32330214
[TBL] [Abstract][Full Text] [Related]
6. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
[TBL] [Abstract][Full Text] [Related]
7. Drug delivery approaches for the treatment of glioblastoma multiforme.
Fakhoury M
Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
[TBL] [Abstract][Full Text] [Related]
8. Blood-brain barrier, cytotoxic chemotherapies and glioblastoma.
Dréan A; Goldwirt L; Verreault M; Canney M; Schmitt C; Guehennec J; Delattre JY; Carpentier A; Idbaih A
Expert Rev Neurother; 2016 Nov; 16(11):1285-1300. PubMed ID: 27310463
[TBL] [Abstract][Full Text] [Related]
9. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends.
Choudhury H; Pandey M; Chin PX; Phang YL; Cheah JY; Ooi SC; Mak KK; Pichika MR; Kesharwani P; Hussain Z; Gorain B
Drug Deliv Transl Res; 2018 Oct; 8(5):1545-1563. PubMed ID: 29916012
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in targeted drug delivery for the treatment of glioblastoma.
Mao M; Wu Y; He Q
Nanoscale; 2024 May; 16(18):8689-8707. PubMed ID: 38606460
[TBL] [Abstract][Full Text] [Related]
11. Bioscaffold-based study of glioblastoma cell behavior and drug delivery for tumor therapy.
Tran K; Brice R; Yao L
Neurochem Int; 2021 Jul; 147():105049. PubMed ID: 33945833
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review.
Liao W; Fan S; Zheng Y; Liao S; Xiong Y; Li Y; Liu J
Curr Med Chem; 2019; 26(31):5862-5874. PubMed ID: 29768997
[TBL] [Abstract][Full Text] [Related]
13. Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme.
Jena L; McErlean E; McCarthy H
Drug Deliv Transl Res; 2020 Apr; 10(2):304-318. PubMed ID: 31728942
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.
Kim M; Ma DJ; Calligaris D; Zhang S; Feathers RW; Vaubel RA; Meaux I; Mladek AC; Parrish KE; Jin F; Barriere C; Debussche L; Watters J; Tian S; Decker PA; Eckel-Passow JE; Kitange GJ; Johnson AJ; Parney IF; Anastasiadis PZ; Agar NYR; Elmquist WF; Sarkaria JN
Mol Cancer Ther; 2018 Sep; 17(9):1893-1901. PubMed ID: 29970480
[TBL] [Abstract][Full Text] [Related]
15. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
Kim SS; Harford JB; Pirollo KF; Chang EH
Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
[TBL] [Abstract][Full Text] [Related]
16. Novel delivery methods bypassing the blood-brain and blood-tumor barriers.
Hendricks BK; Cohen-Gadol AA; Miller JC
Neurosurg Focus; 2015 Mar; 38(3):E10. PubMed ID: 25727219
[TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanisms of Drug Resistance in Glioblastoma.
Dymova MA; Kuligina EV; Richter VA
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203727
[TBL] [Abstract][Full Text] [Related]
18. Identify a Blood-Brain Barrier Penetrating Drug-TNB using Zebrafish Orthotopic Glioblastoma Xenograft Model.
Zeng A; Ye T; Cao D; Huang X; Yang Y; Chen X; Xie Y; Yao S; Zhao C
Sci Rep; 2017 Oct; 7(1):14372. PubMed ID: 29085081
[TBL] [Abstract][Full Text] [Related]
19. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.
Agarwal S; Sane R; Oberoi R; Ohlfest JR; Elmquist WF
Expert Rev Mol Med; 2011 May; 13():e17. PubMed ID: 21676290
[TBL] [Abstract][Full Text] [Related]
20. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]